Strategies to accelerate AAV chromatography process development

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Strategies to accelerate AAV chromatography process development

This webinar aims to provide a technical overview of rapid process development for an adeno-associated virus (AAV) capture step, using AVIPure^® AAV affinity resins as a case study. A high throughput DOE framework will be shared on how to effectively identify desirable conditions for AAV chromatography. The focus will be on discussing essential elements such as resin screening methodologies, involving rapid elution scouting and refinement through OPUS^® RoboColumns® to maximize yield and purity, while ensuring capsid stability.

Strategies for using pre-packed columns will be reviewed, highlighting their potential to enhance process development efficiency by reducing time consumption and improving scalability. We’ll discuss how to implement these columns effectively in various stages of AAV purification to optimize HCP and DNA removal while maximizing yield.

By attending this webinar, participants will gain valuable insights into streamlining their AAV purification steps, enabling them to develop optimal and efficient processes to scale as needed.

Efficacy of AVIPure® AAV affinity resins (including AAV2, 5, 8 & 9, and the new AAV6) in AAV-based processes and how to select the most suitable resin for your specific needs
Scalability options provided by OPUS® Pre-packed Columns, including the flow from Robocolumn® to Minichrom® and process scale OPUS® pre-packed columns, and how to effectively utilize them as you scale your process
Method validation process using OPUS® MiniChrom® Pre-packed columns and how they contribute to ensuring robust and reliable results in AAV process development

Kelley Kearns

Director of Downstream Development at Repligen

Kelley Kearns is the Director of Downstream Development at Repligen and has been instrumental in the development and production of bioprocess affinity chromatography resins, essential for the purification of biopharmaceuticals. With over 5 years in this role, he has shown an exceptional ability to solve complex technical challenges, ensuring the production of high-quality, life-saving medicines. Kelley Kearns is a highly accomplished professional with a successful track record in the development and commercialization of late-stage biopharmaceuticals. His expertise lies in bridging the gap between drug development and manufacturing, with a focus on process improvement and optimization.

In his previous roles, Kelley's contributions have been equally significant. As a Senior Scientist at Dynavax Technologies, he played a key role in supporting routine manufacturing, making critical technical decisions, troubleshooting, and implementing process improvements. At Bristol-Myers Squibb, Kelley managed laboratory studies for downstream process validation and supported commercial process improvements for late-stage biologics. As a Senior Engineer at Merck, Kelley displayed exemplary project management skills, overseeing the design and construction of multimillion-dollar facilities, resulting in enhanced production capabilities and substantial cost savings through process optimization.

Kelley holds a Doctor of Philosophy (Ph.D.) in Chemical Engineering from the University of Delaware, a Master's degree in Chemical Engineering from Rutgers University, and a Bachelor's degree in Chemical Engineering from The Cooper Union for the Advancement of Science and Art.